周三（8月6日）盘中，生物科技巨头安进（Amgen）股价大幅下跌5.98%，截至发稿时报292.60美元。这一跌幅引起了市场的广泛关注，尤其是在公司刚刚公布了超预期的第二季度业绩之后。
根据安进最新发布的财报，公司2025年第二季度调整后每股收益（EPS）达到6.02美元，显著高于分析师预期的5.26美元。公司营收和利润均实现增长，主要得益于核心产品销售表现强劲。这一业绩本应对股价产生积极影响，但市场反应却截然相反。
分析人士指出，安进股价的下跌可能反映了投资者对公司未来增长前景的担忧。尽管本季度业绩亮眼，但市场可能担心这种强劲表现是否可持续。此外，生物制药行业面临的定价压力和日益激烈的竞争也可能影响了投资者情绪。一些投资者可能选择在利好消息发布后获利了结，导致股价承压。然而，要全面了解股价下跌的具体原因，还需要进一步的市场分析和公司指引。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.